Silk Road Medical Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Chas McKhann

Geschäftsführender

US$13.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	0.8%
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	3.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5yrs

Jüngste Management Updates

Recent updates

Silk Road Medical, Inc (NASDAQ:SILK) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 03

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

May 02

Silk Road Medical, Inc's (NASDAQ:SILK) Shares Leap 35% Yet They're Still Not Telling The Full Story

Feb 03

A Piece Of The Puzzle Missing From Silk Road Medical, Inc's (NASDAQ:SILK) 26% Share Price Climb

Dec 20

Is Silk Road Medical (NASDAQ:SILK) Weighed On By Its Debt Load?

Nov 03

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

Aug 05

Shareholders Should Be Pleased With Silk Road Medical, Inc's (NASDAQ:SILK) Price

May 05

Silk Road Medical GAAP EPS of -$0.44 beats by $0.02, revenue of $33.17M beats by $2.14M

Jul 26

Silk Road Medical: Divergence From Alternative Risk Premia Means Lack Of Upside Capture

Jul 19

Silk Road Medical falls after Citigroup downgrades to Sell from Neutral

Jul 11

Is Silk Road Medical (NASDAQ:SILK) Using Too Much Debt?

Jun 09

Silk Road Medical - What A Road It Has Been

Apr 08

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Chas McKhann im Vergleich zu den Einnahmen von Silk Road Medical verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$53m
Dec 31 2023	US$13m	US$106k	-US$56m

Vergütung im Vergleich zum Markt: ChasDie Gesamtvergütung ($USD13.42M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD3.40M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Chas mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Chas McKhann (55 yo)

less than a year

Amtszeit

US$13,423,834

Vergütung

Mr. Charles S. McKhann, also known as Chas, serves as Chief Executive Officer at Silk Road Medical, Inc since November 02, 2023 and serves as Director since 2023. He serves as President, Chief Executive Of...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Charles McKhann	CEO & Director	less than a year	US$13.42m	keine Daten
Lucas Buchanan	CFO & COO	7.9yrs	US$6.62m	0.39% $ 4.2m
Kevin Klemz	EVP, Chief Legal Officer & Secretary	1.8yrs	US$3.64m	0.015% $ 162.6k
Andrew Davis	Chief Commercial Officer	3.9yrs	US$4.87m	0.17% $ 1.8m
Richard Ruedy	Executive Vice President of Clinical	9.9yrs	US$1.97m	0.30% $ 3.2m
Mhairi Jones	Chief Accounting Officer & VP of Finance	6.3yrs	keine Daten	0.19% $ 2.1m
Tammy Leitsinger	Compliance Officer & VP of Medical Affairs	2.4yrs	keine Daten	keine Daten
Jorge O'Hara	Vice President of Marketing	less than a year	keine Daten	keine Daten
Alison Highlander	Vice President of Human Resources	no data	keine Daten	keine Daten
Sumaira MacDonald	Executive Medical Director	5.3yrs	keine Daten	keine Daten
Lynn Lewis	Investors Relations Officer	no data	keine Daten	keine Daten

3.9yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: SILKDas Führungsteam des Unternehmens gilt als erfahren (3.9 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Charles McKhann	CEO & Director	1.4yrs	US$13.42m	keine Daten
Jack Lasersohn	Independent Chairman	17.2yrs	US$263.49k	0.027% $ 292.6k
Elizabeth Weatherman	Independent Director	11.2yrs	US$212.49k	0.38% $ 4.0m
Donald Zurbay	Independent Director	6.3yrs	US$228.14k	0.017% $ 181.6k
Rick Anderson	Independent Director	3.7yrs	US$221.31k	0.015% $ 164.2k
Tony Chou	Independent Director	17.3yrs	US$202.47k	0.20% $ 2.1m
Tanisha Carino	Independent Director	2.9yrs	US$207.47k	0.014% $ 149.0k
Kevin Ballinger	Independent Director	3.5yrs	US$220.47k	0.045% $ 479.0k

5.0yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrener Vorstand: SILKDie Vorstandsmitglieder gelten als erfahren (5 Jahre durchschnittliche Amtszeit).

Silk Road Medical Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Silk Road Medical, Inc, Annual General Meeting, Jun 18, 2024

CFO & COO recently sold US$170k worth of stock

CFO & COO notifies of intention to sell stock

Insufficient new directors

Silk Road Medical Announces Chief Executive Officer Changes

Erica J. Rogers to Retire as Chief Executive Officer of Silk Road Medical, Inc

Recent updates

New minor risk - Shareholder dilution

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Silk Road Medical, Inc (NasdaqGS:SILK) for $1.2 billion.

Price target increased by 13% to US$20.83

Silk Road Medical, Inc (NASDAQ:SILK) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Silk Road Medical, Inc, Annual General Meeting, Jun 18, 2024

Silk Road Medical, Inc to Report Q1, 2024 Results on Apr 30, 2024

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus

CFO & COO recently sold US$170k worth of stock

CFO & COO notifies of intention to sell stock

Silk Road Medical Expands TCAR Portfolio with Launch of Tapered Enroute®? Transcarotid Stent System

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2024

Silk Road Medical, Inc to Report Q4, 2023 Results on Feb 28, 2024

Silk Road Medical, Inc's (NASDAQ:SILK) Shares Leap 35% Yet They're Still Not Telling The Full Story

Insufficient new directors

A Piece Of The Puzzle Missing From Silk Road Medical, Inc's (NASDAQ:SILK) 26% Share Price Climb

New minor risk - Shareholder dilution

Silk Road Medical, Inc Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Silk Road Medical Announces Chief Executive Officer Changes

Is Silk Road Medical (NASDAQ:SILK) Weighed On By Its Debt Load?

Silk Road Medical, Inc to Report Q3, 2023 Results on Nov 08, 2023

Price target decreased by 39% to US$20.88

Erica J. Rogers to Retire as Chief Executive Officer of Silk Road Medical, Inc

Erica J. Rogers to Retire as President of Silk Road Medical, Inc

Chief Commercial Officer recently sold US$146k worth of stock

Chief Commercial Officer notifies of intention to sell stock

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Silk Road Medical, Inc to Report Q2, 2023 Results on Aug 01, 2023

President notifies of intention to sell stock

Price target decreased by 8.6% to US$51.67

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Silk Road Medical, Inc Provides Revenue Guidance for the Year 2023

Chief Commercial Officer exercised options and sold US$261k worth of stock

Shareholders Should Be Pleased With Silk Road Medical, Inc's (NASDAQ:SILK) Price

President exercised options and sold US$229k worth of stock

Chief Commercial Officer exercised options and sold US$234k worth of stock

Is Silk Road Medical (NASDAQ:SILK) A Risky Investment?

President exercised options and sold US$244k worth of stock

President recently sold US$850k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$296k worth of stock

Silk Road Medical, Inc to Report Q4, 2022 Results on Feb 28, 2023

Chief Commercial Officer exercised options and sold US$333k worth of stock

CFO & COO exercised options and sold US$3.9m worth of stock

President exercised options and sold US$300k worth of stock

Chief Commercial Officer exercised options and sold US$341k worth of stock

President exercised options and sold US$523k worth of stock

Price target increased to US$55.00

Chief Commercial Officer exercised options and sold US$347k worth of stock

CFO & COO exercised options and sold US$1.2m worth of stock

Silk Road Medical, Inc Provides Earnings Guidance for the Full Year 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Chief Commercial Officer exercised options and sold US$288k worth of stock

Silk Road Medical, Inc to Report Q3, 2022 Results on Nov 08, 2022

Silk Road Medical, Inc has completed a Follow-on Equity Offering in the amount of $100.000026 million.

Silk Road Medical, Inc Provides Earnings Guidance for the Quarter Ended September 30, 2022

Silk Road Medical announces $100M common stock offering

President exercised options and sold US$407k worth of stock

Chief Commercial Officer exercised options and sold US$292k worth of stock

Is Silk Road Medical (NASDAQ:SILK) Using Too Much Debt?

President exercised options and sold US$420k worth of stock

Silk Road Medical, Inc. Announces First Patient Enrolled in ROADSTER 3 Post Approval Study Evaluating TCAR® System in Treatment of Standard Surgical Risk Patients